NYSE · RFLHealthcarePharmaceuticals

Rafael Holdings financials

$2.03+0.49%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Jul 31
FY24
Jul 31
FY23
Jul 31
FY22
Jul 31
FY21
Jul 31
FY20
Jul 31
FY19
Jul 31
FY18
Jul 31
Revenue$917.0K$637.0K$279.0K$410.0K$802.0K$4.9M$4.9M$4.4M
Gross profit$783.0K$483.0K$279.0K$410.0K$802.0K$4.9M$4.9M$4.4M
Gross margin85.4%75.8%100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$29.2M-$102.6M-$15.0M-$60.5M-$28.2M-$8.5M-$6.7M-$3.8M
Net income-$30.5M-$34.4M-$1.9M-$124.7M-$24.5M-$10.4M-$4.7M-$11.6M
Net margin−3328.2%−5401.9%−672.4%−30404.4%−3060.3%−212.1%−95.2%−266.5%
Diluted EPS$-1.04$-1.45$-0.08$-6.31$-1.49$-0.66$-0.35$-0.93
EBITDA-$25.8M-$102.4M-$15.0M-$60.4M-$21.1M-$6.6M-$4.9M-$2.1M
Operating cash flow-$18.9M-$7.8M-$10.9M-$26.1M-$15.6M-$4.7M-$3.1M-$1.8M
Free cash flow-$18.9M-$7.9M-$10.9M-$26.1M-$15.6M-$5.2M-$3.5M-$2.5M
Diluted shares29.4M23.7M23.3M19.8M16.5M15.8M13.3M12.5M

Balance sheet

Period endJul 31Jul 31Jul 31Jul 31Jul 31Jul 31
Cash & equivalents$52.8M$2.7M$21.5M$26.5M$7.9M$6.2M
Short-term investments$0.00$63.3M$58.0M$36.7M$0.00—
Total debt$692.0K$2.4M$0.00$15.0M$14.5M$0.00
Total assets$114.1M$96.8M$98.8M$118.3M$154.1M$136.3M
Total liabilities$15.7M$10.6M$2.2M$21.1M$17.4M$5.8M
Shareholders' equity$98.4M$86.3M$96.6M$97.2M$136.7M$130.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology